Get the Stockscreener App
0.00
100.00%
-11.13
After Hours:
11.20
11.20
+
Verve Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.
See More
Previous Close:
$11.13
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$994.04M
Revenue:
$20.65M
Net Income/Loss:
$-192.65M
P/E Ratio:
0.00
EPS:
-2.59
Net Cash Flow:
$-134.39M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$11.40
Verve Therapeutics Inc Stock (VERV) Company Profile
Name
Verve Therapeutics Inc
Sector
Industry
Phone
(978) 501-3026
Address
201 BROOKLINE AVENUE, BOSTON
Compare VERV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERV
Verve Therapeutics Inc
|
0.00 | 994.04M | 20.65M | -192.65M | -134.39M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.04 | 115.56B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
703.26 | 75.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.02 | 60.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
900.76 | 55.48B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
196.55 | 43.51B | 447.02M | -1.18B | -906.14M | -6.1812 |
Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Apr-08-24 | Initiated | H.C. Wainwright | Buy |
| Apr-13-23 | Initiated | Canaccord Genuity | Buy |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-15-22 | Initiated | Goldman | Sell |
| Oct-06-22 | Initiated | Credit Suisse | Neutral |
| Aug-25-22 | Upgrade | Stifel | Hold → Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-21 | Initiated | Stifel | Hold |
| Jul-12-21 | Initiated | Guggenheim | Buy |
| Jul-12-21 | Initiated | JP Morgan | Neutral |
| Jul-12-21 | Initiated | Jefferies | Buy |
| Jul-12-21 | Initiated | William Blair | Outperform |
View All
Verve Therapeutics Inc Stock (VERV) Latest News
Is Verve Therapeutics Inc. stock a safe haven asset2025 Geopolitical Influence & Expert-Curated Trade Recommendations - Newser
Will Verve Therapeutics Inc. stock maintain dividend yieldPortfolio Value Report & Real-Time Volume Analysis Alerts - Newser
Will Verve Therapeutics Inc. stock deliver shareholder valueJuly 2025 Reactions & Free Growth Oriented Trading Recommendations - Newser
Will Verve Therapeutics Inc. stock deliver consistent dividendsEarnings Trend Report & Safe Capital Growth Trade Ideas - Newser
Is Verve Therapeutics Inc. stock positioned for digital transformationDividend Hike & Target Return Focused Picks - BỘ NỘI VỤ
Aug Gainers: Can Verve Therapeutics Inc. stock beat analyst upgradesJuly 2025 Patterns & AI Forecasted Entry and Exit Points - BỘ NỘI VỤ
Is Verve Therapeutics Inc. stock a bargain at current levels2025 Momentum Check & Fast Gaining Stock Reports - BỘ NỘI VỤ
Can Verve Therapeutics Inc. stock attract ESG capital inflows2025 Volatility Report & Safe Swing Trade Setup Alerts - BỘ NỘI VỤ
Verve Therapeutics Inc Stock Analysis and ForecastMoving Average Strategies & Unlock Free Weekly Portfolio Checkups - earlytimes.in
What insider trading reveals about Verve Therapeutics Inc. stockMarket Trend Report & Stock Portfolio Risk Control - newser.com
Price momentum metrics for Verve Therapeutics Inc. explained2025 Support & Resistance & Technical Confirmation Trade Alerts - newser.com
Is Verve Therapeutics Inc. stock in correction or buying zoneRate Hike & Entry Point Strategy Guides - newser.com
How resilient is Verve Therapeutics Inc. stock in market downturnsWeekly Stock Analysis & AI Enhanced Market Trend Forecasts - newser.com
What drives Verve Therapeutics Inc stock pricePrice-to-Earnings Ratio Insights & Rapid Profit Portfolio - earlytimes.in
Automated trading signals detected on Verve Therapeutics Inc.July 2025 Breakouts & Reliable Trade Execution Plans - newser.com
Can Verve Therapeutics Inc. stock withstand economic slowdownWeekly Investment Report & Fast Moving Trade Plans - newser.com
Verve Therapeutics Inc. stock daily chart insightsQuarterly Trade Report & Growth Focused Entry Reports - newser.com
Sector ETF performance correlation with Verve Therapeutics Inc.Rate Cut & Risk Adjusted Buy/Sell Alerts - newser.com
Is Verve Therapeutics Inc. stock entering bullish territoryWeekly Market Outlook & Daily Price Action Insights - newser.com
Is Verve Therapeutics Inc. stock a safe buy before earningsProduct Launch & Verified High Yield Trade Plans - newser.com
How to track smart money flows in Verve Therapeutics Inc.Earnings Overview Summary & Safe Entry Point Identification - newser.com
Will Verve Therapeutics Inc. stock continue dividend increases2025 EndofYear Setup & Risk Managed Investment Entry Signals - Fundação Cultural do Pará
Technical analysis overview for Verve Therapeutics Inc. stockEarnings Recap Summary & AI Driven Stock Movement Reports - newser.com
Has Verve Therapeutics Inc. formed a bullish divergenceGap Up & Entry Point Strategy Guides - newser.com
Will Verve Therapeutics Inc. bounce back from current supportTrade Signal Summary & Safe Capital Allocation Plans - newser.com
Verve Therapeutics Inc Stock (VERV) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.67%
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):